Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBT Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBT Margin for 15 consecutive years, with 13.07% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 1262.0% to 13.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 14.06%, a 517.0% increase, with the full-year FY2025 number at 14.06%, up 517.0% from a year prior.
  • EBT Margin was 13.07% for Q4 2025 at Niagen Bioscience, down from 14.12% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 25.7% in Q4 2024 to a low of 51.17% in Q3 2021.
  • A 5-year average of 10.41% and a median of 5.9% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -2158bps in 2021, then soared 3612bps in 2023.
  • Niagen Bioscience's EBT Margin stood at 29.98% in 2021, then surged by 77bps to 6.88% in 2022, then surged by 108bps to 0.54% in 2023, then soared by 4678bps to 25.7% in 2024, then plummeted by -49bps to 13.07% in 2025.
  • Per Business Quant, the three most recent readings for NAGE's EBT Margin are 13.07% (Q4 2025), 14.12% (Q3 2025), and 12.01% (Q2 2025).